SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending due to high volume and trader activity, with community members pointing to recent price gains and comparing it to other DeFi gainers. Conversations suggest excitement around its features, potential for new all-time highs, and speculation about hitting certain price targets.  Some users are also mentioning the project's backers and the possibility of listings on major exchanges.

PHUMPTOM (PHUM) is a meme token, the symbol of which is a phantom. The story of this character is built around trading, and according to legend, he was born on the pump platform.fun from the energy of green candles. Now it is a symbol of green charts, the keeper of green candles. His presence portends growth, and he brings good luck to traders.  A positive character who tells his story like an adventure, generates memes where he always rushes to the aid of traders and gives good luck to holders.

PHUMPTOM

PHUM.X is gaining attention as a potential "sleeper gem" within the Solana ecosystem, with community members actively encouraging others to buy in early. The token is generating buzz, with many highlighting its chart strength and anticipating a breakout. Some users are also emphasizing the importance of teamwork and community support for the token's success.

TOSHI

TOSHI.X is trending strongly as the community celebrates recent listings on multiple exchanges and anticipates further expansion. Bullish sentiment is fueled by the coin's association with Coinbase and the Base network, with many community members expressing excitement about its potential for significant gains. The conversation highlights a growing belief that Toshi is poised for substantial growth in the meme coin sector.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors discuss the potential for a violent short squeeze, citing high short interest and borrow fees. Community members are focused on the upcoming Type A meeting minutes and HOPE-3 data, with some expressing concerns about the FDA's review process. Discussions also highlight the real-world impact of Capricor's therapy on patients' lives and the potential for FDA approval.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around this Solana-based meme coin and its 'Updog' namesake. Active discussions revolve around its strong community, long-term development, and potential for a meme-driven surge similar to other popular dog-themed tokens in the crypto space.

Story is a purpose-built layer 1 blockchain designed specifically to onramp intellectual property (IP) to the blockchain and make it programmable.  Story tokenizes any type of IP; whether that’s an idea, an image, a real world asset, a song, an AI model, an NFT or anything in-between. By embedding usage terms, attribution, and royalty agreements directly into the blockchain, Story provides a transparent, decentralized solution for IP management. This enables IP holders to protect their work, collaborate on IP seamlessly, and unlock revenue opportunities in an AI-powered economy.

Story Protocol

Story Protocol ($IP.X) is trending as traders discuss its potential in the AI and IP space, noting recent exchange listings and a limited coin supply. Community members are sharing bullish price predictions and analyzing technical indicators, while also drawing comparisons to other trending tokens like $KAITO.X. Some investors are excited about potential partnerships with major AI/robotics companies and upcoming announcements.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as discussions revolve around the potential impacts of President Trump's policies on visa holders and the company's response. Community members are also analyzing JPM's financials, with some suggesting it's overvalued and ripe for a pullback, while others highlight its strong earnings and potential for growth in various sectors. Additionally, the company's strategic moves, such as its Asia expansion, partnership with Plaid, and potential takeover of Apple's credit card program, are fueling investor interest and debate.

Boundless is a universal protocol that brings ZK to every chain. Using Boundless, developers can create expressive, high-throughput applications that bypass traditional block size/gas limits.  Developers submit proof requests and provers compete to fulfill them, earning direct rewards and protocol-level incentives through proof of verifiable work.  By abstracting away the complexity of proof generation, aggregation, and onchain settlement, Boundless allows developers to build without worrying about underlying infrastructure, while provers provide strong liveness guarantees, censorship-resistance, and continuously improve the cost curve driven by open market dynamics.  This architecture decouples execution from consensus and introduces a new paradigm for verifiable computing. As the number of Boundless prover nodes grows, the total capacity of the protocol increases, scaling compute across every chain.

Boundless

Boundless ($ZKC.X) is trending as community members highlight its potential in scaling blockchain technology, citing strong volume and a favorable risk/reward profile. Discussions revolve around upcoming dashboards, audits, partnerships, and bridges potentially acting as catalysts. Some community members are comparing its potential to other cryptocurrencies.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending due to its upcoming merger with Infleqtion, a quantum computing company, generating excitement as a potentially undervalued pure-play in the sector. The community is comparing it to other quantum stocks like $IONQ and $RGTI, while also highlighting Infleqtion's existing contracts and revenue. Some are also speculating about the potential of its warrants.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending due to discussions around increased Vazkepa prescriptions in England and a potential buyout following an updated corporate overview, sparking speculation about a deal with Novartis. The community is analyzing data suggesting strong growth in EU scripts and the implications of Sarissa's involvement, interpreting recent corporate actions as strategic positioning for acquisition. Analysts are pointing to the company's cash position, reduced expenses, and potential for revenue growth as positive factors, while highlighting both near and long-term catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  AxoGen (AXGN) This Year?

Here is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.

Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging  Arcutis Biotherapeutics (ARQT) This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

Arcutis Biotherapeutics Inc.'s stock jumped 8.7% in after-hours trading on Tuesday following a stronger-than-expected fourth-quarter performance, driven by surging demand for its flagship inflammatory dermatology treatment.&nbsp;The upbeat results ignited a sharp rise in retail investor engagement, with message volume on Stocktwits soaring nearly 430% and sentiment shifting from ‘neutral’ to ‘bullish’ within a day.<figure class="image"><img style="aspect-ratio:1266/724;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ARQT_message_volume_meter_as_of_Feb_25_2a89fcb8eb.png" alt="ARQT message volume meter as of Feb 25.png" width="1266" height="724"><figcaption>ARQT message volume meter as of Feb 25 | source: Stocktwits</figcaption></figure>The company reported a fourth-quarter loss per share of $0.09, significantly better than the anticipated loss of $0.26.&nbsp;Revenue hit $71.4 million, well above the consensus estimate of $60.52 million.&nbsp;Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.CEO Frank Watanabe attributed the company's strong momentum to a well-executed pricing and access strategy and the successful commercial launch of two new Zoryve indications in 2024.Retail investors reacted enthusiastically, with one user calling the earnings report a "10/10 release."&nbsp;<stembedurl>https://stocktwits.com/Dilly_Poppins/message/605742985</stembedurl>Another investor speculated that given Zoryve's rapid growth and multiple indications, Arcutis could become an attractive acquisition target for larger biopharma companies.<stembedurl>https://stocktwits.com/lyonsa14/message/605727827</stembedurl>Chief Commercial Officer L. Todd Edward said the company plans to introduce a new foam formulation of Zoryve for body and scalp psoriasis in the second half of the year. A pediatric label expansion is also in the pipeline.&nbsp;He highlighted strong Medicaid coverage and ongoing Medicare Part D negotiations as key factors that could help Arcutis deepen its market penetration.The company said it ended 2024 with $228.6 million in cash and marketable securities and has significantly reduced interest expenses after repaying $100 million in debt in October.&nbsp;Arcutis reaffirmed its target of reaching cash flow break-even in 2026.According to Koyfin data, short interest in the stock last stood at 16.2%, down from 19.7% at the beginning of the year. Despite the after-hours rally, Arcutis shares are down more than 14% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

Equity

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.


Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a 'Clear Win for Your Skin' Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a 'Clear Win for Your Skin' PR Newswire...

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Arcutis Biotherapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

ARQT
Arcutis Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARQT News

ARQT Arcutis Biotherapeutics Inc